# HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06769425/  
OnCo record `nct06769425` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06769425 as recruiting, last updated 2025-06-24. Enrolment is 157 planned participants, an estimate. Interventions: HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib, HS-10502 + HS-20089, HS-10502 + Platinum + Bevacizumab, HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan, HS-10502 + Bevacizumab. Primary measures include Maximum tolerated dose (MTD) of HS-10502（Stage 1：Dose escalating stage）; Maximum applicable dose (MAD) of HS-10502（Stage 1：Dose escalating stage）. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06769425
- Phase: 1
- Setting: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 Combination Treatment in Subjects With Advanced Solid Tumors
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

## Sources

- ClinicalTrials.gov NCT06769425: https://clinicaltrials.gov/study/NCT06769425

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HS-10502](https://onco.cc/drugs/hs-10502/)

---
JSON: https://onco.cc/api/v1/entities/nct06769425.json